{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:13:59Z","timestamp":1783329239553,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) in HCV-infected pediatric chronic kidney disease (CKD) patients on maintenance hemodialysis (HD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-center, prospective single-arm observational exploratory study assessing the efficacy and safety of a 12-week course of sofosbuvir\/ledipasvir (SOF\/LDV) for the treatment of chronic HCV in Egyptian children and adolescents, 6\u201317\u00a0years old, who have CKD on regular HD. Potential adverse events (AE) were reported at baseline and during treatment administration using a detailed questionnaire. Sustained virological response (SVR12) was the primary study outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The present study included 22 CKD patients on maintenance HD therapy. Their age ranged from 7.5 to 15.9\u00a0years with a median (IQR) of 12 (9.25\u201313.5) years. They were diagnosed with CKD stage 5 and scheduled for regular HD at a median (IQR) age of 6 (3.5\u20139) years (range 2\u201312\u00a0years). The median (IQR) baseline quantitative HCV RNA was 62,446 (6875\u2013604,000) IU\/L. During treatment, one patient experienced severe vomiting necessitating discontinuation of SOF\/LDV. The remaining 21 patients completed the treatment course. The reported AE were all mild, and there were no reported serious adverse events. Nineteen out of 22 patients (86.4%) achieved SVR12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SOF\/LDV was found to be effective in the treatment of HCV in children and adolescents with CKD on HD with SVR12 86.4%, with no serious adverse events recorded.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-025-07112-6","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:10:20Z","timestamp":1773022220000},"page":"2583-2590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of SOF\/LDV in HCV-infected children and adolescents on hemodialysis: a prospective single-center observational study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-1678","authenticated-orcid":false,"given":"Afaf","family":"Enayet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaa","family":"El-Karaksy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engy","family":"Mogahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Yasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haytham","family":"Ghita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"7112_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3748\/wjg.v21.i2.408","volume":"21","author":"RJ Carvalho-Filho","year":"2015","unstructured":"Carvalho-Filho RJ, Feldner AC, Silva AE, Ferraz ML (2015) Management of hepatitis C in patients with chronic kidney disease. World J Gastroenterol 21:408\u2013422. https:\/\/doi.org\/10.3748\/wjg.v21.i2.408","journal-title":"World J Gastroenterol"},{"key":"7112_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00535-017-1427-x","volume":"53","author":"G Suda","year":"2018","unstructured":"Suda G, Ogawa K, Morikawa K et al (2018) Treatment of hepatitis C in special populations. J Gastroenterol 53:591\u2013605. https:\/\/doi.org\/10.1007\/s00535-017-1427-x","journal-title":"J Gastroenterol"},{"key":"7112_CR3","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.kint.2022.07.013","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group (2022) KDIGO 2022 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 102:S129\u2013S205. https:\/\/doi.org\/10.1016\/j.kint.2022.07.013","journal-title":"Kidney Int"},{"key":"7112_CR4","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1093\/ndt\/gfab072","volume":"37","author":"ME Sise","year":"2022","unstructured":"Sise ME, McQuaid T, Martin P (2022) Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. Nephrol Dial Transplant 37:2327\u20132334. https:\/\/doi.org\/10.1093\/ndt\/gfab072","journal-title":"Nephrol Dial Transplant"},{"key":"7112_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ekir.2022.11.008","volume":"8","author":"EM Balk","year":"2022","unstructured":"Balk EM, Adam GP, Jadoul M, Martin P, Gordon CE (2022) A systematic review of direct-acting antivirals for hepatitis C in advanced CKD. Kidney Int Rep 8:240\u2013253. https:\/\/doi.org\/10.1016\/j.ekir.2022.11.008","journal-title":"Kidney Int Rep"},{"key":"7112_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000204","volume":"93","author":"AEM Aly Abd Elrazek","year":"2014","unstructured":"Aly Abd Elrazek AEM, Bilasy SE, Elbanna AEM, Elsherif AEA (2014) Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore) 93:e204. https:\/\/doi.org\/10.1097\/MD.0000000000000204","journal-title":"Medicine (Baltimore)"},{"key":"7112_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IJGM.S119301","volume":"10","author":"A Elgharably","year":"2016","unstructured":"Elgharably A, Gomaa AI, Crossey MM, Norsworthy PJ, Waked I, Taylor-Robinson SD (2016) Hepatitis C in Egypt\u2013past, present, and future. Int J Gen Med 10:1\u20136. https:\/\/doi.org\/10.2147\/IJGM.S119301","journal-title":"Int J Gen Med"},{"key":"7112_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/apt.14799","volume":"48","author":"AA Butt","year":"2018","unstructured":"Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra AB (2018) Effectiveness, treatment completion and safety of sofosbuvir\/ledipasvir and paritaprevir\/ritonavir\/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther 48:35\u201343","journal-title":"Aliment Pharmacol Ther"},{"key":"7112_CR9","unstructured":"AASLD-IDSA (2022) Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org. Last updated: October 24, 2022, Accessed on November 20, 2024"},{"key":"7112_CR10","unstructured":"Gilead Sciences, Inc. Harvoni (ledipasvir and sofosbuvir) tablets, for oral use [Prescribing Information]. Foster City, CA; 2020. Accessed November 7, 2025"},{"key":"7112_CR11","unstructured":"Gilead Sciences, Inc. Harvoni (ledipasvir and sofosbuvir) tablets, for oral use [Prescribing Information]. Foster City, CA; 2024. Accessed November 7, 2025. Available from: https:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/liver-disease\/harvoni\/harvoni_pi.pdf"},{"key":"7112_CR12","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Published November 27, 2017. Accessed November 11, 2025"},{"key":"7112_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","volume":"66","author":"D Wyles","year":"2017","unstructured":"Wyles D, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Martin R, Afdhal NH et al (2017) Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir\/sofosbuvir. J Hepatol 66:703\u2013710. https:\/\/doi.org\/10.1016\/j.jhep.2016.11.022","journal-title":"J Hepatol"},{"key":"7112_CR14","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/liv.13025","volume":"36","author":"HE Nazario","year":"2016","unstructured":"Nazario HE, Ndungu M, Modi AA (2016) Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml\/min. Liver Int 36:798\u2013801. https:\/\/doi.org\/10.1111\/liv.13025","journal-title":"Liver Int"},{"key":"7112_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.4254\/wjh.v7.i3.548","volume":"7","author":"S Marinaki","year":"2015","unstructured":"Marinaki S, Boletis JN, Sakellariou S, Delladetsima IK (2015) Hepatitis C in hemodialysis patients. World J Hepatol 7:548\u2013558","journal-title":"World J Hepatol"},{"key":"7112_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/jir.2016.0019","volume":"36","author":"EA Mogahed","year":"2016","unstructured":"Mogahed EA, Abdelaziz H, Helmy H, Ghita H, Abdel Mawla MA, Hassanin F, Fadel FI, El-Karaksy H (2016) Safety and efficacy of pegylated interferon alpha-2b monotherapy in hepatitis C virus-infected children with end-stage renal disease on hemodialysis. J Interferon Cytokine Res 36:681\u2013688. https:\/\/doi.org\/10.1089\/jir.2016.0019","journal-title":"J Interferon Cytokine Res"},{"key":"7112_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/ajkd.2001.21294","volume":"37","author":"S Saab","year":"2001","unstructured":"Saab S, Martin P, Brezina M et al (2001) Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis. Am J Kidney Dis 37:308\u2013315","journal-title":"Am J Kidney Dis"},{"key":"7112_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3350\/cmh.2016.0087","volume":"23","author":"HP Shin","year":"2017","unstructured":"Shin HP, Park JA, Burman B, Kozarek RA, Siddique A (2017) Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. Clin Mol Hepatol 23:316\u2013322. https:\/\/doi.org\/10.3350\/cmh.2016.0087","journal-title":"Clin Mol Hepatol"},{"key":"7112_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/liv.13102","volume":"36","author":"V Saxena","year":"2016","unstructured":"Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NA (2016) Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36:807\u2013816. https:\/\/doi.org\/10.1111\/liv.13102","journal-title":"Liver Int"},{"key":"7112_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","volume":"16","author":"M Li","year":"2019","unstructured":"Li M, Chen J, Fang Z, Li Y, Lin Q (2019) Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4\u20135 chronic kidney disease: a systematic review and meta-analysis. Virol J 16:34. https:\/\/doi.org\/10.1186\/s12985-019-1140-x","journal-title":"Virol J"},{"key":"7112_CR21","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.14309\/ajg.0000000000001281","volume":"116","author":"WL Chuang","year":"2021","unstructured":"Chuang WL, Hu TH, Buggisch P, Moreno C, Su WW, Biancone L, Camargo M, Hyland R, Lu S, Kirby BJ, Dvory-Sobol H, Osinusi A, Gaggar A, Peng CY, Liu CH, Sise ME, Mangia A (2021) Ledipasvir\/sofosbuvir for 8, 12, or 24 weeks in hepatitis C patients undergoing dialysis for end-stage renal disease. Am J Gastroenterol 116:1924\u20131928. https:\/\/doi.org\/10.14309\/ajg.0000000000001281","journal-title":"Am J Gastroenterol"},{"key":"7112_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/liv.14299","volume":"40","author":"R Eletreby","year":"2020","unstructured":"Eletreby R, El-Serafy M, Anees M, Kasem G, Salama M, Elkhouly R, Hamdy M, Abdel Haleem H, Kamal E, Abdel-Razek W, Salama R, Elshenawy M, Shafeek A, Hassany M, El-Sayed MH, El-Shazly Y, Esmat G (2020) Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver Int 40:797\u2013805. https:\/\/doi.org\/10.1111\/liv.14299","journal-title":"Liver Int"},{"key":"7112_CR23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MPG.0000000000002101","volume":"67","author":"H El-Karaksy","year":"2018","unstructured":"El-Karaksy H, Mogahed EA, Abdullatif H, Ghobrial C, El-Raziky MS, El-Koofy N, El-Shabrawi M, Ghita H, Baroudy S, Okasha S (2018) Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with sofosbuvir\/ledipasvir. J Pediatr Gastroenterol Nutr 67:626\u2013630. https:\/\/doi.org\/10.1097\/MPG.0000000000002101","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"Suppl2","key":"7112_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcae175.479","volume":"117","author":"W Abd Elhamid Eid","year":"2024","unstructured":"Abd Elhamid Eid W, Bahnacy AA, GadAllah AA, Abdel Wahed AS (2024) HCV relapse in hemodialysis Egyptian patients after treatment with direct acting antiviral drugs. QJM 117(Suppl2):hcae175.479. https:\/\/doi.org\/10.1093\/qjmed\/hcae175.479","journal-title":"QJM"},{"key":"7112_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s43066-022-00196-x","volume":"12","author":"HAE Elshinnawy","year":"2022","unstructured":"Elshinnawy HAE, Sarhan II, Ahmed OA et al (2022) Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus. Egypt Liver J 12:36. https:\/\/doi.org\/10.1186\/s43066-022-00196-x","journal-title":"Egypt Liver J"},{"key":"7112_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.9734\/ijtdh\/2025\/v46i21631","volume":"46","author":"R Elsaied","year":"2025","unstructured":"Elsaied R, Omar A, Atlam S, Gabr M (2025) Prevalence of hepatitis C virus infection in hemodialysis patients in Egypt: a systematic review. International Journal of Tropical Disease & Health 46:74\u201385. https:\/\/doi.org\/10.9734\/ijtdh\/2025\/v46i21631","journal-title":"International Journal of Tropical Disease & Health"},{"key":"7112_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","volume":"65","author":"A Desnoyer","year":"2016","unstructured":"Desnoyer A, Pospai D, L\u00ea MP, Gervais A, Heurgu\u00e9-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, Fontaine H, Zucman D, Simonpoli AM, Muret P, Larrouy L, Bernard Chabert B, Descamps D, Yazdanpanah Y, Peytavin G (2016) Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 65:40\u201347. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.044","journal-title":"J Hepatol"},{"key":"7112_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/hdi.12604","volume":"22","author":"M Surendra","year":"2018","unstructured":"Surendra M, Raju SB, Sridhar N, Vijay Kiran B, Rajesh G, Anvesh G, Raju N (2018) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: a prospective observational study. Hemodial Int 22:217\u2013221. https:\/\/doi.org\/10.1111\/hdi.12604","journal-title":"Hemodial Int"},{"key":"7112_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.dld.2018.09.012","volume":"51","author":"C Ghobrial","year":"2019","unstructured":"Ghobrial C, Sobhy R, Mogahed E, Abdullatif H, El-Karaksy H (2019) Is sofosbuvir\/ledipasvir safe for the hearts of children with hepatitis C virus? Dig Liver Dis 51:258\u2013262. https:\/\/doi.org\/10.1016\/j.dld.2018.09.012","journal-title":"Dig Liver Dis"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-07112-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:14:14Z","timestamp":1783325654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-07112-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7112"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-07112-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by\u00a0the Cairo University Research Ethics Committee (REC: A-4-2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consents were obtained from patients\u2019 guardians before drug administration, where risks and benefits were thoroughly discussed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}